Corrigendum: Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients - a nationwide and longitudinal study

Front Oncol. 2025 Mar 26:15:1595028. doi: 10.3389/fonc.2025.1595028. eCollection 2025.

¹ Oslo Economics, Oslo, Norway.
² Pfizer AS, Oslo, Norway.
³ Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
⁴ Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.
⁵ Department of Respiratory Medicine, Oslo University Hospital, Oslo, Norway.
⁶ Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway.
⁷ Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
⁸ Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.

Abstract

[This corrects the article DOI: 10.3389/fonc.2025.1506041.].

Keywords: ALK; EGFR; ROS; lung cancer; real world data; time on treatment.